[Federal Register Volume 87, Number 203 (Friday, October 21, 2022)]
[Notices]
[Pages 64067-64068]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22887]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Opportunity To Co-Sponsor Office of Research Integrity Events

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Office of Research Integrity (ORI) announces the 
opportunity for non-federal public and private sector entities to co-
sponsor ORI conferences, workshops, symposia, meetings, roundtables, or 
other such events (collectively, ``Events''). ORI co-sponsors a limited 
number of events with non-federal entities each year. Potential co-
sponsors must have demonstrated interest and experience in the 
responsible conduct of research or handling allegations of research 
misconduct. Potential co-sponsors must be willing to participate 
substantively in the co-sponsored event.

DATES: Expressions of interest for co-sponsorship of an ORI Event may 
be submitted on an ongoing basis throughout the fiscal year (October 1, 
2022-September 30, 2023) or beyond.

ADDRESSES: Expressions of interest for co-sponsorship of an ORI Event 
should be sent by email to [email protected] with ``Co-sponsorship for ORI 
Event'' in the subject field.

FOR FURTHER INFORMATION CONTACT: 

Tracey Randolph, Program Analyst, Office of Research Integrity, 1101 
Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453-8200

SUPPLEMENTARY INFORMATION: ORI oversees and directs U.S. Public Health 
Service (PHS) research integrity

[[Page 64068]]

activities on behalf of the Secretary of the U.S. Department of Health 
and Human Services (HHS), with the exception of the regulatory research 
integrity activities of the Food and Drug Administration. ORI is a 
program office within the Office of the Assistant Secretary for Health, 
Office of the Secretary, HHS.
    Core to ORI's mission is the support of education and outreach 
activities that aid PHS-funded research institutions in their efforts 
``to teach the responsible conduct of research, promote research 
integrity, prevent research misconduct, and . . . to respond 
effectively to allegations of research misconduct'' (65 FR 30600, 30601 
(May 12, 2000)). ORI Events contribute to this mission by providing 
education, training, and/or the opportunity for discussion related to 
topics such as handling allegations of research misconduct and 
fostering research integrity and the responsible conduct of research. 
ORI Events typically are moderately sized, usually accepting between 20 
and 150 attendees, and convened in person or virtually for one to three 
days.
    Co-sponsors will work with ORI staff to jointly develop an event. 
Both ORI and the co-sponsor must contribute substantively to the 
development of the event. Co-sponsors can charge registration fees to 
recover costs associated with the events; however, co-sponsors may not 
set registration fees at an amount higher than necessary to recover 
event-related expenses. Further, co-sponsors are solely responsible for 
collecting and handling any registration fees.
    Eligibility for Co-Sponsorship: The co-sponsoring entity must have 
demonstrated interest and experience in fostering the responsible 
conduct of research or handling of research misconduct allegations. The 
co-sponsoring entity must participate substantively in the co-sponsored 
activity, and not just provide funding, logistical services, or other 
material support.
    Expression of Interest in Co-Sponsorship: An entity shall provide 
an expression of interest that includes (1) one to two paragraphs 
detailing why ORI should select the entity, including the entity's 
leadership in and management of matters involving research integrity 
and the responsible conduct of research, and (2) a bulleted outline 
addressing the seven topics listed below. The expression of interest 
should be one to two pages in length, single-spaced, and at least 11-
point font. An entity may submit an expression of interest individually 
or jointly with other entities describing their relative contributions. 
The seven topics to be addressed in the outline are:

1. The entity's interest and goals in promoting research integrity and/
or the responsible conduct of research
2. The entity's prior experience and current readiness to undertake the 
responsibilities described above
3. The type of event(s) that the entity is interested in co-sponsoring 
with ORI
4. Facilities available for the event(s), including the distance from 
the facilities to a major airport
5. Any current constraints with respect to dates or facilities
6. Whether the entity has co-sponsored an ORI Event in the past 36 
months
7. Whether the entity has any cases, allegations, or other related 
matters pending with ORI

    Evaluation Criteria: After engaging in exploratory discussions with 
potential co-sponsors who respond to this notice, HHS will apply the 
following considerations, as appropriate and relevant, to select the 
co-sponsor(s):

 Qualifications and capability to fulfill co-sponsorship 
responsibilities
 Suitability of the location of the proposed event in terms of 
the overall geographical distribution of recent or planned ORI Events
 Potential for reaching, generating, and engaging an adequate 
number of attendees
 Availability and description of facilities needed to support 
the event
 Availability of administrative support for the logistics of 
hosting such events

    The duties of the co-sponsor will be outlined in a co-sponsorship 
agreement with ORI that will set forth the details of the co-sponsored 
event, including the requirements that any fees collected by the co-
sponsor shall be limited to the amount necessary to cover the co-
sponsor's event-related expenses. This co-sponsorship agreement does 
not represent an endorsement by ORI of an individual co-sponsor's 
policies, positions, or activities.

    Dated: October 13, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant 
Secretary for Health.
[FR Doc. 2022-22887 Filed 10-20-22; 8:45 am]
BILLING CODE 4150-31-P